# TROPiCS-02 (NCT03901339)

> Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03901339
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Gilead Sciences
- Conditions: Metastatic Breast Cancer
- Interventions: Sacituzumab Govitecan-hziy; Eribulin; Capecitabine; Gemcitabine; Vinorelbine
- Enrollment: 543
- Primary outcome: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment

## Commentary we found

- Podcasts: 62
- YouTube: 59
- X threads: 58

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=tropics-02-nct03901339

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03901339", "email": "<work email>"}; the inbox owner confirms by the emailed link.